Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Has the Implantable Cardioverter Defibrillators (ICDs) Market Growth Performance Trended Historically, And What Lies Ahead?

The market for implantable cardioverter defibrillators (ICDs) has shown significant growth in the recent past. Predictions suggest an increase from $3.76 billion in 2024 to $3.99 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.0%. Factors contributing to this rise during the historical period include a surge in cases of sudden cardiac arrest, the use of the implantable cardioverter defibrillator in preventing secondary sudden cardiac arrest instances, heightened public knowledge, an increase in the elderly population, encouraging policies from governing bodies and healthcare institutions, and improved accessibility to healthcare.

The market for implantable cardioverter defibrillators (ICDs) is poised for substantial expansion in the forthcoming years, with projections indicating growth to $4.99 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.8%. This growth, predicted for the forecast period, is attributable to factors such as increased adoption of implantable defibrillators, demand surge for customized cardiac care, increasing incidents of cardiac rhythm issues, and growing demand in budding markets. The forecast period is also set to witness several trends including technological progression, launch of subcutaneous ICDs eliminating the need for transvenous leads, demand surge for combined ICD devices with pacemaker capabilities, improved sensing and detection algorithms, persistent advancements in wireless charging and battery technology, and the advent of artificial intelligence (AI) in healthcare and data analytics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20839&type=smp

What Are the Core Market Drivers Propelling Growth in the Implantable Cardioverter Defibrillators (ICDs) Industry?

The proliferating incidence of heart-related illnesses, collectively referred to as cardiovascular diseases (CVDs), is predicted to significantly contribute to the expansion of the implantable cardioverter defibrillators (ICDs) market. CVDs encompass a variety of afflictions impacting the heart and blood vessels like stroke, hypertension, and heart attacks, frequently resulting from genetics, inadequate physical activity, smoking, and poor dietary habits. The rising prevalence is predominantly attributed to aging populace, unhealthy lifestyle habits, and spiking frequency of risk factors such as hypertension, diabetes, and obesity. To combat such conditions, implantable cardioverter defibrillators (ICDs) are employed to deliver crucial electrical shocks to restore regular heart patterns for those facing the danger of unanticipated cardiac arrest. Drawing from a December 2023 report from the Australian Institute of Health and Welfare, a governmental body based in Australia, deaths validated by doctors due to coronary heart disease (CHD) accelerated to 14,100 in 2021 and further augmented to 14,900 in 2022. Therefore, the escalating prevalence of cardiovascular diseases (CVDs) is stimulating the expansion of the implantable cardioverter defibrillators (ICDs) market.

How Is the Implantable Cardioverter Defibrillators (ICDs) Market Segmented?

The implantable cardioverter defibrillators (ICDs) market covered in this report is segmented –

1) By Type: Single Chamber Implantable Cardioverter Defibrillators (ICDs), Dual Chamber Implantable Cardioverter Defibrillators (ICDs), Biventricular Devices

2) By Applications: Bradycardia, Tachycardia, Heart Failure, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Single Chamber Implantable Cardioverter Defibrillators (ICDs): Standard Single Chamber ICDs, MRI-Compatible Single Chamber ICDs, Wireless Single Chamber ICDs

2) By Dual Chamber Implantable Cardioverter Defibrillators (ICDs): Standard Dual Chamber ICDs, MRI-Compatible Dual Chamber ICDs, Wireless Dual Chamber ICDs

3) By Biventricular Devices: CRT-D (Cardiac Resynchronization Therapy Defibrillator), CRT-P (Cardiac Resynchronization Therapy Pacemaker), Biventricular ICDs With Advanced Features (Remote Monitoring, Wireless Capabilities)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20839&type=smp

Which Regions Are Driving the Next Phase of the Implantable Cardioverter Defibrillators (ICDs) Market Growth?

North America was the largest region in the implantable cardioverter defibrillators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable cardioverter defibrillators (ICDs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering the Implantable Cardioverter Defibrillators (ICDs) Market Direction?

Significant players in the implantable cardioverter defibrillators (ICDs) market are striving to advance technology to increase device efficacy, extend battery life, and boost patient comfort. This includes development of low current consumption defibrillators that use less energy when delivering electric shocks to the heart, effectively extending battery life and treating arrhythmias. A case in point is the October 2023 release of the ULYS implantable cardioverter defibrillator (ICD) and INVICTA defibrillation lead in Japan by MicroPort CRM, a French medical device company. This marked significant progress in cardiac care technology. Their devices boast innovative features such as low current consumption for increased battery longevity and MRI compatibility, making them perfect for patients requiring imaging procedures. The ULYS ICD features the PARAD+ arrhythmia discrimination algorithm and AutoMRI capabilities, guaranteeing patient safety during MRI scans. In addition, the INVICTA lead had an outstanding record in clinical trials, achieving a 100% implantation success rate and a 97.4% complication-free rate, demonstrating its reliability and efficiency.

View the full report here:

https://www.thebusinessresearchcompany.com/report/implantable-cardioverter-defibrillators-icds-global-market-report

How Is the Implantable Cardioverter Defibrillators (ICDs) Market Defined and What Are Its Core Parameters?

Implantable cardioverter defibrillators (ICDs) are small devices implanted under the skin, typically near the chest, designed to monitor the heart’s rhythm and deliver electrical shocks if a life-threatening arrhythmia, such as ventricular fibrillation, is detected. Their purpose is to prevent sudden cardiac arrest by restoring a normal heart rhythm.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20839

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model